Equities
Health CarePharmaceuticals and Biotechnology
  • Price (SEK)105.20
  • Today's Change-3.80 / -3.49%
  • Shares traded430.26k
  • 1 Year change-18.70%
  • Beta0.5100
Data delayed at least 15 minutes, as of Feb 11 2026 17:00 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Biogaia AB is a Sweden-based healthcare company that is engaged in the development and sell of probiotic products. The Company develops, markets and sells probiotic products with documented health benefits. The products are primarily based on different strains of the lactic acid bacterium Limosilactobacillus reuteri. The Company’s activities are divided into three segments: The Paediatrics segment drops, gut health tablets, oral rehydration solution (ORS) and cultures to be used as ingredients in licensee products; The Adult Health segment (gut health tablets, oral health lozenges and cultures as an ingredient in a licensee’s dairy products) and the Other (royalties in respect of development projects, revenue from packaging solutions in the subsidiary CapAble, etc.). The Company operates worldwide.

  • Revenue in SEK (TTM)1.46bn
  • Net income in SEK315.92m
  • Incorporated1990
  • Employees238.00
  • Location
    Biogaia ABKungsbroplan 3STOCKHOLM 112 27SwedenSWE
  • Phone+46 855529300
  • Fax+46 855529301
  • Websitehttps://sv.biogaia.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Flerie AB0.00-757.00m2.76bn2.00--0.8166-----9.76-9.760.0043.600.00-------19.86-18.21-19.95-18.51---367.55---1,314.83---0.04890.0006---100.00---231.97------
Swedencare AB (publ)2.67bn63.00m3.86bn609.0060.990.564610.331.440.3960.39616.7842.770.27883.639.864,776,250.000.65361.160.67951.2033.6036.002.344.401.523.940.201544.568.6282.0968.7727.0269.3912.30
BioGaia AB1.46bn315.92m10.74bn238.0034.909.0536.957.343.123.1214.4612.040.8623----6,499,662.0018.6314.7620.8916.0372.7173.0621.6027.38----0.00129.549.7313.11-3.8213.40-18.3633.95
Bonesupport Holding AB1.12bn151.92m11.78bn143.0078.1914.2972.5810.532.292.2916.8312.521.260.62056.268,811,984.0017.065.1420.116.3192.6191.4013.575.593.9219.360.01330.0052.0542.04-45.41--5.71--
Vimian Group AB4.44bn331.08m13.87bn1.20k41.861.9218.933.120.63010.63018.4613.750.3861.837.563,703,500.003.01--3.31--68.61--7.80--1.3914.270.2796--12.95--88.01------
Bavarian Nordic A/S9.74bn3.46bn21.85bn1.74k6.371.164.902.2430.5730.5785.79168.130.47321.346.084,274,910.0016.803.3120.184.0254.3352.6835.509.802.43--0.01010.00-19.0653.88-33.03---8.77--
Camurus AB2.35bn781.67m41.38bn280.0053.0310.0551.4917.5813.0313.0339.2568.790.57461.135.649,195,492.0019.088.6521.1910.4693.5091.3133.2112.0110.30--0.02520.008.7877.63-0.7065--1.29--
Data as of Feb 11 2026. Currency figures normalised to Biogaia AB's reporting currency: Swedish Krona SEK

Institutional shareholders

24.74%Per cent of shares held by top holders
HolderShares% Held
Fj�rde AP-fondenas of 31 Mar 20258.20m8.33%
Premier Fund Managers Ltd.as of 17 Jun 20253.01m3.06%
Janus Henderson Investors UK Ltd.as of 31 Dec 20252.46m2.49%
Teknik Innovation Norden Fonder ABas of 31 Mar 20252.00m2.03%
Handelsbanken Fonder ABas of 31 Jan 20261.64m1.66%
JPMorgan Asset Management (UK) Ltd.as of 31 Dec 20251.50m1.52%
Allianz Global Investors GmbHas of 31 Oct 20251.50m1.52%
AMF Fonder ABas of 30 Jun 20251.42m1.44%
Montanaro Asset Management Ltd.as of 31 Dec 20251.33m1.35%
BlackRock Fund Advisorsas of 09 Jan 20261.32m1.34%
More ▼
Data from 30 Sep 2025 - 31 Jan 2026Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.